

Vincent Lo Re

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1415620/vincent-lo-re-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

3,961
citations

37
h-index

58
g-index

162
ext. papers

4,760
ext. citations

5
avg, IF

5.43
L-index

#	Paper	IF	Citations
155	Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?". <i>Journal of Hepatology</i> , 2022 ,	13.4	
154	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV.. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022 , 89, 396-404	3.1	0
153	Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.. <i>Pharmacoepidemiology and Drug Safety</i> , 2022 ,	2.6	2
152	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6	1
151	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 338-346	1.5	
150	The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. <i>PLoS ONE</i> , 2021 , 16, e0258143	3.7	0
149	A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 827-837	2.6	5
148	Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 899-909	2.6	0
147	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
146	Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. <i>Hepatology</i> , 2021 , 74, 1190-1202	11.2	8
145	Global covid-19 vaccine rollout and safety surveillance-how to keep pace. <i>BMJ, The</i> , 2021 , 373, n1416	5.9	5
144	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021 , 37, 338-346	1.5	0
143	Development and validation of case-finding algorithms to identify prosthetic joint infections after total knee arthroplasty in Veterans Health Administration data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1184-1191	2.6	1
142	Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e417-e425	9.5	0
141	Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1353-1360	6.1	0
140	Validation of health outcomes of interest in healthcare databases 2021 , 207-218		0
139	Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 602-609	2.6	2

138	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021 , 4, e2037512	10.4	4
137	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. <i>BMJ Global Health</i> , 2021 , 6,	6.6	2
136	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. <i>Journal of Hepatology</i> , 2021 , 75, 1312-1322	13.4	3
135	The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. <i>Hepatology</i> , 2021 , 74, 566-581	11.2	2
134	The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 873-881	1.9	1
133	Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e639-e650	9.5	2
132	Determinants of stigma among patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1179-1189	3.4	5
131	Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. <i>Journal of Hepatology</i> , 2020 , 73, 277-284	13.4	18
130	Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. <i>Current HIV/AIDS Reports</i> , 2020 , 17, 405-414	5.9	11
129	Differences in Pathology, Staging, and Treatment between HIV and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 71-78	4	3
128	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 184-191	8.5	7
127	Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3159-3174	4	1
126	Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection. <i>PLoS ONE</i> , 2020 , 15, e0228471	3.7	5
125	Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020 , 35, 2025-2034	4	3
124	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1067-1071	9.5	6
123	Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 1592-1602	6.1	4
122	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 530-534	3.1	
121	Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years 2020 ,		67

120	Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans 2020 ,		46
119	HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 747-755	9.7	10
118	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. <i>Scientific Reports</i> , 2020 , 10, 18729	4.9	1
117	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. <i>PLoS Medicine</i> , 2020 , 17, e1003379	11.6	149
116	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
115	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study 2020 , 17, e1003379		
114	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study 2020 , 17, e1003379		
113	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study 2020 , 17, e1003379		
112	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study 2020 , 17, e1003379		
111	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019 , 6, e93-e104	7.8	58
110	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. <i>BMC Gastroenterology</i> , 2019 , 19, 52	3	4
109	Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results From the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCHIVES). <i>Clinical Infectious Diseases</i> , 2019 , 68, 857-859	11.6	11
108	Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1328-1335	2.6	3
107	A SEMIPARAMETRIC MODELING APPROACH USING BAYESIAN ADDITIVE REGRESSION TREES WITH AN APPLICATION TO EVALUATE HETEROGENEOUS TREATMENT EFFECTS. <i>Annals of Applied Statistics</i> , 2019 , 13, 1989-2010	2.1	5
106	Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 815-826	7.4	16
105	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 71-80	3.1	10
104	2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S82-S82	1	78
103	Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. <i>Aids</i> , 2018 , 32, 739-749	3.5	48

102	Bilirubin Is Inversely Associated With Cardiovascular Disease Among HIV-Positive and HIV-Negative Individuals in VACS (Veterans Aging Cohort Study). <i>Journal of the American Heart Association</i> , 2018 , 7, 7,	6	27
101	Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States. <i>Current Hepatology Reports</i> , 2018 , 17, 111-120	1	8
100	Bayesian nonparametric generative models for causal inference with missing at random covariates. <i>Biometrics</i> , 2018 , 74, 1193-1202	1.8	12
99	Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1147-1150	2.6	3
98	Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. <i>Liver International</i> , 2018 , 38, 813-820	7.9	21
97	Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy076	1	49
96	The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. <i>Hepatology</i> , 2018 , 67, 2244-2253	11.2	100
95	2224. Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S657-S658	1	78
94	2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S655-S656	1	78
93	Mortality and Kidney Transplantation Outcomes among Chronic Dialysis Patients who are Seropositive for Hepatitis C Virus. <i>Transplantation</i> , 2018 , 102, S154	1.8	
92	Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. <i>Annals of Epidemiology</i> , 2018 , 28, 808-811	6.4	2
91	FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. <i>Hepatology</i> , 2017 , 66, 1286-1295	11.2	17
90	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. <i>Clinical Infectious Diseases</i> , 2017 , 65, 64-72	11.6	23
89	Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1542-1550	11.6	7
88	Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1172-1181	2.6	6
87	The Reply. <i>American Journal of Medicine</i> , 2017 , 130, e369	2.4	
86	Evaluation of methods to estimate missing daysSupply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 115-123	2.8	3
85	Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx012	1	4

84	Development and Usability of a Smartphone Application for Tracking Antiretroviral Medication Refill Data for Human Immunodeficiency Virus. <i>Methods of Information in Medicine</i> , 2017 , 56, 351-359	1.5	7
83	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000400	4.5	13
82	The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S41-S41	1	1
81	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , 2016 , 65, S33-S45	5.4	111
80	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 918-919	6.9	
79	Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 930-6	4	36
78	Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. <i>American Journal of Medicine</i> , 2016 , 129, 283-91.e5	2.4	43
77	Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 285-93	4.2	15
76	Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1035-43	6.9	97
75	HIV, Aging, and Viral Coinfections: Taking the Long View. <i>Current HIV/AIDS Reports</i> , 2016 , 13, 269-78	5.9	19
74	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1160-1167	11.6	43
73	Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. <i>Journal of Substance Abuse Treatment</i> , 2016 , 68, 62-7	4.2	2
72	Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of HyB Law and a New Prognostic Model. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2360-8	6.9	43
71	Liver fibrosis progression in hepatitis C virus infection after seroconversion. <i>JAMA Internal Medicine</i> , 2015 , 175, 178-85	11.5	61
70	Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv109	1	10
69	Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women. <i>Journal of Infectious Diseases</i> , 2015 , 212, 924-33	7	17
68	Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. <i>Gastroenterology</i> , 2015 , 148, 1353-61.e3	13.3	67
67	Validity of Primary Immunodeficiency Disease Diagnoses in United States Medicaid Data. <i>Journal of Clinical Immunology</i> , 2015 , 35, 566-72	5.7	8

66	Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 999-1003	2.6	16
65	Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 676-83	2.6	13
64	Epidemiologic research using probabilistic outcome definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 19-26	2.6	4
63	Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. <i>AIDS Research and Treatment</i> , 2015 , 2015, 923194	2.3	11
62	Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. <i>AIDS Research and Treatment</i> , 2015 , 2015, 653840	2.3	1
61	Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 93	2.8	10
60	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. <i>BMC Pharmacology & Toxicology</i> , 2015 , 16, 8	2.6	5
59	Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 936-47	3.4	11
58	Should everyone ageing with HIV take a statin?. <i>Lancet HIV,the</i> , 2015 , 2, e36-7	7.8	0
57	Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 288-96	3.4	19
56	Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007. <i>Annals of Epidemiology</i> , 2014 , 24, 418-23	6.4	15
55	Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2014 , 61, 210-8	13.4	17
54	Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1449-58	11.6	66
53	Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. <i>Annals of Internal Medicine</i> , 2014 , 160, 369-79	8	183
52	The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e101554	3.7	290
51	HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. <i>Current HIV Research</i> , 2014 , 12, 50-9	1.3	14
50	1603Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S427-S427	1	78
49	645Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S33-S33	1	78

48	Colorectal cancer incidence and screening in US Medicaid patients with and without HIV infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014 , 26, 716-22	2.2	14
47	Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1027-31	11.6	9
46	Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. <i>Clinical Infectious Diseases</i> , 2014 , 58, 719-27	11.6	41
45	Reply to Marcellin et al. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1192-3	11.6	
44	Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. <i>AIDS and Behavior</i> , 2013 , 17, 94-103	4.3	5
43	Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 103-7	2.6	39
42	Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1352-6	2.6	12
41	Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 861-72	2.6	45
40	Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. <i>Journal of Clinical Gastroenterology</i> , 2013 , 47, 457-60	3	1
39	Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. <i>Hepatology</i> , 2012 , 56, 1688-98	11.2	59
38	Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, 962-8	4.5	20
37	Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 765-769	2.6	102
36	Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 1202-15	2.6	20
35	Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 1266-74	5.8	29
34	Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. <i>Annals of Internal Medicine</i> , 2011 , 155, 353-60	8	49
33	The Yale cTAKES extensions for document classification: architecture and application. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011 , 18, 614-20	8.6	62
32	Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 689-99	2.6	105
31	FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2512-7	4	37

30	Economic analysis of hepatitis B screening and treatment. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1307-9	11.6	4
29	The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. <i>Antiviral Therapy</i> , 2010 , 15, 91-9	1.6	18
28	Adherence to hepatitis C virus therapy and early virologic outcomes. <i>Clinical Infectious Diseases</i> , 2009 , 48, 186-93	11.6	61
27	Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. <i>Aids</i> , 2009 , 23, 2191-8	3.5	29
26	Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 807-14	2.6	51
25	Effect of race and HIV co-infection upon treatment prescription for hepatitis C virus. <i>International Journal of Infectious Diseases</i> , 2009 , 13, 449-55	10.5	13
24	Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. <i>HIV Clinical Trials</i> , 2009 , 10, 25-32		14
23	Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy. <i>Journal of the Cardiometabolic Syndrome</i> , 2008 , 3, 111-4		15
22	Incidence of transaminitis among HIV-infected patients with occult hepatitis B. <i>Journal of Clinical Virology</i> , 2008 , 43, 32-6	14.5	6
21	Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. <i>Clinics in Liver Disease</i> , 2008 , 12, 587-609, ix	4.6	28
20	The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 818-25	2.6	7
19	Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 315-20	3.1	56
18	Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 44, 344-50	3.1	12
17	Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. <i>Journal of Clinical Epidemiology</i> , 2007 , 60, 294-9	5.7	8
16	Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. <i>Aids</i> , 2006 , 20, 1333-6	3.5	27
15	A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. <i>Journal of Infectious Diseases</i> , 2006 , 194, 1108-14	7	157
14	William Pepper Jr, MD (1843-1898): portrait of a nineteenth-century medical educator. <i>Journal of Medical Biography</i> , 2006 , 14, 169-77	0.4	
13	Type III hyperlipoproteinemia unmasked by HIV anti-retroviral therapy. <i>American Journal of Medicine</i> , 2005 , 118, 691-2	2.4	2

12	Natural history of patients with low-level HIV viremia on antiretroviral therapy. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 436-42	5.8	7
11	Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1789-90; author reply 1790	11.6	3
10	Identifying the vector of Lyme disease. <i>American Family Physician</i> , 2004 , 69, 1935-7	1.3	4
9	Travel immunizations. <i>American Family Physician</i> , 2004 , 70, 89-99	1.3	6
8	Anemia during treatment of hepatitis C in HIV-infected patients. <i>Aids Reader</i> , 2004 , 14, 555-7, 562, 565-71		3
7	Hypereosinophilia associated with cardiac rhabdomyosarcoma. <i>American Journal of Hematology</i> , 2003 , 74, 64-7	7.1	9
6	Eosinophilic meningitis. <i>American Journal of Medicine</i> , 2003 , 114, 217-23	2.4	137
5	Prevention of malaria in travelers. <i>American Family Physician</i> , 2003 , 68, 509-14	1.3	5
4	Fever in the returned traveler. <i>American Family Physician</i> , 2003 , 68, 1343-50	1.3	17
3	Eosinophilic meningitis due to <i>Gnathostoma spinigerum</i> . <i>Journal of Infection</i> , 2002 , 45, 117-20	18.9	14
2	Eosinophilic meningitis due to <i>Angiostrongylus cantonensis</i> in a returned traveler: case report and review of the literature. <i>Clinical Infectious Diseases</i> , 2001 , 33, e112-5	11.6	28
1	Infected branchial cleft cyst due to <i>Bordetella bronchiseptica</i> in an immunocompetent patient. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 4210-2	9.7	18